Article thumbnail

The Role of Proteoglycans in Contributing to Placental Thrombosis and Fetal Growth Restriction

By Joanne M. Said


Fetal growth restriction is an important pregnancy complication that has major consequences for the fetus and neonate as well as an increased risk of long-term morbidity extending into adulthood. The precise aetiology of most cases of fetal growth restriction is unknown although placental thrombosis is a common feature in many of these cases. This paper will outline the potential role of proteoglycans in contributing to placental thrombosis and fetal growth restriction

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2002). Absence of association of thrombophilia polymorphisms with intrauterine growth restriction,”
  2. (2005). Altered perlecan expression in placental development and gestational diabetes mellitus,”
  3. (1998). Anticoagulantdermatansulfateproteoglycan(decorin)inthe term human placenta,” Thrombosis Research,v o l .9 0 ,n o .4 ,p p .
  4. (2005). Basement membrane proteoglycans: from cellar to ceiling,”
  5. (2000). Characterization of proteoglycans of human placenta and identification of unique chondroitin sulfate proteoglycans of the intervillous spaces that mediate the adherenceofPlasmodiumfalciparum-infectederythrocytesto the placenta,”
  6. (2005). Characterization of the structure of antithrombin-binding heparan sulfate generated by heparan sulfate 3-O-sulfotransferase 5,”
  7. (2002). Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product,”
  8. (2008). D.Iacob,J.Cai,M.Tsoniset al.,“Decorin-mediated inhibition of proliferation and migration of the human trophoblast via different tyrosine kinase receptors,”
  9. (2006). Fetal growth restriction: pathogenic mechanisms,”
  10. (2006). Fetal growth restriction: the etiology,” Clinical Obstetrics and Gynecology,
  11. (1995). Fetal thrombotic vasculopathy: the clinical significance of extensive avascular villi,”
  12. (2003). Haemostatic mechanisms in human placenta,”
  13. (2007). High glucose alters proteoglycan expression and the glycosaminoglycan composition in placentas of women with gestational diabetes mellitus and in cultured trophoblasts,”
  14. (2002). How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review,”
  15. (1990). Increased intravascular coagulation associated with pregnancy,”ObstetricsandGynecology,vol.75,no.3I,pp.385–389,
  16. (2010). Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women,”
  17. (2001). Intraplacental coagulation in intrauterine growth restriction: cause or result?”
  18. (1995). Intrauterine growth restriction in infants of less than thirty-two weeks’ gestation: associated placental pathologic features,”
  19. (2008). Is human placenta proteoglycan remodeling involved in pre-eclampsia?”
  20. (2001). Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia,”
  21. (1998). o k i m a a ,P .I n k i ,H .K u j a r i ,O .H i r v o n e n ,E .E k h o l m ,a n d L. Anttila, “Expression of syndecan-1 in human placenta and decidua,”
  22. (1993). P .B a r k e r ,P .D .G l u c k m a n ,K .M .G o d f r e y
  23. (2009). Placental Biglycan Expression is Decreased in
  24. (2006). Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor
  25. (1997). Placental pathology of absent and reversed end-diastolic flow in growth- restricted fetuses,”
  26. (2009). Placental Syndecan-1 expression is signifi-cantlyreducedinidiopathicfetalgrowthrestriction,”Placenta,
  27. (1998). Pre-eclampsia—still a disease of theories?”
  28. (2000). Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy,”
  29. (2004). Reformable intramolecular cross-linking of the N-terminal domain of heparin cofactor II: effects on enzyme inhibition,”
  30. (1995). S a l a fi a ,J .C .P e z z u l l o
  31. (2005). Sunderk¨ o t t e r ,R .V .I o z z o ,a n dL .S c h a e f e r , “Decorin, a novel player in the insulin-like growth factor system,”
  32. (2008). The HAPO Study Cooperative Research Group, “Hyperglycemia and adverse pregnancy outcomes,” The New England
  33. (2005). The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus,”
  34. (2006). Thrombophilia in pregnancy: a systematic review,”